---
title: Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis
nct_id: NCT02953379
overall_status: WITHDRAWN
phase: PHASE3
sponsor: EMS
study_type: INTERVENTIONAL
primary_condition: Allergic Rhinitis
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02953379.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02953379"
ct_last_update_post_date: 2020-11-04
last_seen_at: "2026-05-12T06:59:18.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis

**Official Title:** Phase III, National, Multicenter, Randomized, Single-blind, Non-inferiority to Compare the Efficacy of Mometasone Nasal Gel Compared to Mometasone Nasal Spray in the Treatment of Persistent or Intermittent Allergic Rhinitis in Adults

**NCT ID:** [NCT02953379](https://clinicaltrials.gov/study/NCT02953379)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Sponsor decision
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** EMS
- **Conditions:** Allergic Rhinitis
- **Start Date:** 2019-05
- **Completion Date:** 2020-03
- **CT.gov Last Update:** 2020-11-04

## Brief Summary

The purpose of this study is to evaluate the non-inferiority of the clinical efficacy of the mometasone nasal gel in the treatment of allergic rhinitis.

## Eligibility

- **Minimum age:** 12 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Signed Consent of the patient;
* Clinical diagnosis of moderate - severe persistent allergic rhinitis according to ARIA classification(Allergic Rhinitis and Its Impact on Asthma);

Exclusion Criteria:

* Patients with any clinically significant disease that in the investigator is opinion can

  ´t participate in the study;
* Patients with any laboratory finding or image finding that in the investigator is opinion can´t participate in the clinical trial;
* Patients with history of hypersensitivity to any of the formula compounds;
* Participation in clinical trial in the year prior to this study;
* Pregnancy or risk of pregnancy and lactating patients;
* Patients who were in use of drugs that can interfere with evaluation;
* Decongestants dependent patients or patients receiving allergen specific immunotherapy;
* Patients on treatment with monoamine oxidase inhibitors (MAOIs);
* History of hypertension, coronary artery disease, cardiac arrhythmias, glaucoma, hyperthyroidism and / or prostatic hypertrophy.
```

## Arms

- **EMS Mometasone gel** (EXPERIMENTAL) — The patient should administer 2 spray in each nostril, once daily.
- **Mometasone spray nasal** (ACTIVE_COMPARATOR) — The patient should administer 2 spray in each nostril, once daily.

## Interventions

- **EMS Mometasone gel** (DRUG) — The patient should administer 2 spray in each nostril, once daily.
- **Mometasone spray nasal** (DRUG) — The patient should administer 2 spray in each nostril, once daily.

## Primary Outcomes

- **Efficacy of allergic rhinitis treatment based proportion of participants who show at least moderate relief** _(time frame: 14 days)_

## Secondary Outcomes

- **Safety will be evaluated by the adverse events occurrences** _(time frame: 14 days)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02953379.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02953379*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*